US2020237912A1PendingUtilityA1

Method for the treatment or prevention of infection-related immune conditions using a composition comprising igm

65
Assignee: GRIFOLS WORLDWIDE OPERATIONS LTDPriority: Aug 6, 2015Filed: Apr 15, 2020Published: Jul 30, 2020
Est. expiryAug 6, 2035(~9 yrs left)· nominal 20-yr term from priority
Inventors:Thomas BarnettDavid Ross
Y02A50/30A61K 45/06A61K 38/1722A61K 38/14A61P 31/00A61K 2300/00A61K 9/0019A61K 38/40A61K 31/407A61K 39/395C07K 2317/76C07K 2317/73C07K 2317/70C07K 2317/52C07K 16/00A61K 39/40A61P 37/02C07K 16/1214A61P 43/00A61P 31/04A61K 39/39516C07K 16/1232C07K 16/1228A61P 37/06A61K 2039/545A01K 67/0275C07K 16/1282
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.

Claims

exact text as granted — not AI-modified
1 - 52 . (canceled) 
     
     
         53 . A composition comprising IgM. 
     
     
         54 . The composition according to  claim 53 , characterized in that the composition used has at least 90% (w/v) of IgM purity. 
     
     
         55 . The composition according to  claim 53 , characterized in that the composition has a 95% (w/v) of IgM purity. 
     
     
         56 . The composition according to  claim 53 , characterized in that IgM is recombinant. 
     
     
         57 . The composition according to  claim 53 , characterized in that IgM is plasma-derived. 
     
     
         58 . The composition according to  claim 53 , characterized in that IgM is cell culture-derived. 
     
     
         59 . The composition according to  claim 53 , characterized in that IgM is transgenic. 
     
     
         60 . The composition according to  claim 53 , characterized in that IgM is or chemically synthesized. 
     
     
         61 . The composition according to  claim 57 , wherein IgM is plasma-derived IgM and is isolated from a suitable fraction of plasma. 
     
     
         62 . The composition according to  claim 53 , characterized in that the composition further comprises one or more anti-inflammatory molecules, small molecule antibiotics, molecules that are antimicrobial in nature, natural or synthetic peptide antimicrobials, proteins with antimicrobial properties, other immunomodulators or combinations thereof. 
     
     
         63 . The composition according to  claim 62 , hat the composition further comprises vancomycin, meropenem, lactoferrin or combinations thereof.

Join the waitlist — get patent alerts

Track US2020237912A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.